Authors: T. Yang, X. Li, Y. Liu, S. Bai
Affilation: Husson University, United States
Pages: 318 - 321
Keywords: nanoparticles, VEGF, SiRNA
Recent discovery of small interfering RNA (SiRNA) that silences growth factors appears to improve effectiveness and safety of cancer therapy. Unfortunately, delivery of SiRNA to cancer cells is a major obstacle. Our work is focused on a known and successful therapeutic target ̶ vascular endothelial growth factor (VEGF) for lung cancer therapy. The objective of this work is to develop VEGF SiRNA nanoparticle delivery systems to safely and effectively treat lung cancer via pulmonary administration. Our central hypothesis is nanocarriers of SiRNA will inhibit the expression and activity of VEGF in lung cancer cells with high efficiency, low toxicity, and long duration of effect. Results of the work will provide significant insights to improve the therapeutic outcomes for lung cancer patients. Our long term goal is to develop new pharmaceuticals to improve the safety and efficacy of lung cancer treatments by novel drug delivery systems.
Nanotech Conference Proceedings are now published in the TechConnect Briefs